- Ellen Kullman, the chair and chief executive officer of DuPont, will retire.1
- The settlement is the largest in the department’s history.3
- The tentative agreement on trade negotiated by a dozen Pacific-rim nations will slightly pry open Japan’s famously closed rice market, amongst other things.4
- Airbus Group SE’s A380 faces a test of its true value as Singapore Airlines Ltd. considers whether to return the world’s first superjumbo to its owner in 2017 following the expiration of 10-year lease contract, air-finance banker Bertrand Grabowski said.6
- John Brynjolfsson, the chief investment officer of Armored Wolf, said he is closing the money management firm to outside investors and converting it into a family office that will oversee his own wealth, after its largest fund was hit by the slump in commodities.7
- Central Bank is targeting balance sheet, expanding U.S. debt.8
- The bond market shows traders see only an 8 percent chance the Federal Reserve will raise interest rates at its Oct. 27-28 meeting10
- The incident came a day after a Russian warplane violated Turkish air space before exiting into Syria.11
- Carly Fiorina is looking like the insider's outsider candidate.12
- Trian Fund Management, the activist firm co-founded by Nelson Peltz, took a $2.5 billion stake in General Electric.14
- Suncor Energy offered to acquire all outstanding shares of Canadian Oil Sands Ltd. for about $3.3 billion.15
- Russia’s finance minister said he plans to meet his Ukrainian counterpart this week to discuss a $3 billion Eurobond.16
- U.S. stocks surged to cap their longest rally of the year, as speculation the Federal Reserve will keep interest rates lower for longer boosted riskier assets from commodities to emerging-market equities. Junk bonds climbed.
- A single, 5,000 percent price hike on an anti-parasitic drug made by Turing Pharmaceuticals garnered national media attention. But it’s just one of hundreds of smaller price increases drug companies make in the U.S. each year, a tactic the industry uses to generate more revenue from older medications.